Finalization of the Project: Creation of an Open Scientific Repository of Stem Cells Derived from Individuals with ARCA1-type Ataxia

The Ataxia Canada Foundation thanks CDPQ for the financial support provided to the research. This project aimed to reprogram patient-derived cells into induced pluripotent stem cells (iPSC) for the study of ARCA1, a disease for which there is a significant lack of representative cellular models. Impact of this Research: Specific...

Continue reading

Today, we present Sébastien Huynh

Conversation with women and men engaged in our foundation. Today, we present Sébastien HUYNH | LinkedIn. AC: Can you introduce your professional background? SH: My career has allowed me to develop broad skills in management, finance, and accounting. Having grown up in France, I have had the opportunity to work...

Continue reading

U.S. Food & Drug Administration Approves Reata Pharmaceuticals’ SKYCLARYS™ for the Treatment of Adults and Adolescents Aged 16 Years and Older with Freidreich Ataxia

U.S. Food & Drug Administration Approves Reata Pharmaceuticals’ SKYCLARYS™ (Omaveloxolone) for the Treatment of Adults and Adolescents Aged 16 Years and Older with FA   Montreal,QC ., February 28, 2023 – This week  marks the approval of the first medication to treat Friedreich’s Ataxia (FA), a milestone for the FA...

Continue reading